Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19700578 | 1.00 | HRH3 (0.45) | HRH3MAOBSIGMAR1HRH2HRH1 | |
| SCHEMBL19700572 | 1.00 | HRH3 (0.45) | HRH3MAOBSIGMAR1HRH2HRH1 | |
| SCHEMBL26787071 | 0.90 | HRH3 (0.55) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL26787061 | 0.90 | HRH3 (0.55) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL12788357 | 0.89 | KDM4E (0.40) | HRH3MAOBSIGMAR1 | |
| SCHEMBL10192108 | 0.89 | HRH3 (0.51) | HRH3MAOBSIGMAR1HRH2HRH1 | |
| SCHEMBL21743256 | 0.83 | HRH3 (0.43) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL19709043 | 0.83 | HRH3 (0.43) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL19709379 | 0.83 | HRH3 (0.43) | HRH3MAOBHRH2HRH1 | |
| SCHEMBL10025524 | 0.81 | HRH3 (0.46) | HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | HRH3 2154/4885MAOB 1361/4885SIGMAR1 3983/4885 |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | HRH3 1076/4885MAOB 390/4885SIGMAR1 786/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | HRH3 2154/4885MAOB 1361/4885SIGMAR1 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.